These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 35263743)

  • 1. Secukinumab Drug Survival in Psoriasis and Psoriatic Arthritis Patients: A 24-Month Real-Life Study.
    Ortolan A; Lorenzin M; Leo G; Pampaloni F; Messina F; Doria A; Piaserico S; Ramonda R
    Dermatology; 2022; 238(5):897-903. PubMed ID: 35263743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study.
    Kiltz U; Sfikakis PP; Gaffney K; Sator PG; von Kiedrowski R; Bounas A; Gullick N; Conrad C; Rigopoulos D; Lespessailles E; Romanelli M; Ghislain PD; Brandt-Jürgens J; Rashkov R; Aassi M; Orsenigo R; Perella C; Pournara E; Gathmann S; Jagiello P; Veit J; Augustin M
    Adv Ther; 2020 Jun; 37(6):2865-2883. PubMed ID: 32378070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
    Deodhar A; Mease PJ; McInnes IB; Baraliakos X; Reich K; Blauvelt A; Leonardi C; Porter B; Das Gupta A; Widmer A; Pricop L; Fox T
    Arthritis Res Ther; 2019 May; 21(1):111. PubMed ID: 31046809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement.
    Adami G; Idolazzi L; Benini C; Fracassi E; Carletto A; Viapiana O; Gatti D; Rossini M; Fassio A
    Reumatismo; 2023 May; 75(1):. PubMed ID: 37154254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of secukinumab in patients with psoriasis and psoriatic arthritis in a Saudi real-world setting.
    Al-Homood IA; Alajlan M; Alberdisi M; Alturki M; Ahmed AA; Zakaria N
    Adv Rheumatol; 2024 Apr; 64(1):34. PubMed ID: 38685124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psoriatic arthritis, biologic therapy experience, body mass index, and onset age of psoriasis were independent factors of secukinumab discontinuation in patients with psoriasis.
    Akdogan N; Balan K; Armagan BY; Gulseren D; Dogan S
    Expert Rev Clin Pharmacol; 2024 Aug; 17(8):755-762. PubMed ID: 38994659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study.
    Ramonda R; Lorenzin M; Carriero A; Chimenti MS; Scarpa R; Marchesoni A; Lubrano di Scorpaniello E; Salvarani C; Cauli A; Semeraro A; Santo L; Ortolan A; Doria A; Fracassi E; Virelli G; Masia M; Fanizzi R; Visalli E; Amato G; Carletto A; Foti R;
    RMD Open; 2021 Feb; 7(1):. PubMed ID: 33593933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients.
    Ortolan A; Lorenzin M; Tadiotto G; Russo FP; Oliviero F; Felicetti M; D'Incà R; Favero M; Piaserico S; Doria A; Ramonda R
    Clin Rheumatol; 2019 Oct; 38(10):2843-2850. PubMed ID: 31254236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries.
    Michelsen B; Georgiadis S; Di Giuseppe D; Loft AG; Nissen MJ; Iannone F; Pombo-Suarez M; Mann H; Rotar Z; Eklund KK; Kvien TK; Santos MJ; Gudbjornsson B; Codreanu C; Yilmaz S; Wallman JK; Brahe CH; Möller B; Favalli EG; Sánchez-Piedra C; Nekvindova L; Tomsic M; Trokovic N; Kristianslund EK; Santos H; Löve TJ; Ionescu R; Pehlivan Y; Jones GT; van der Horst-Bruinsma I; Ørnbjerg LM; Østergaard M; Hetland ML
    Arthritis Care Res (Hoboken); 2022 Jul; 74(7):1205-1218. PubMed ID: 33460531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment persistence of interleukin-17 inhibitor class drugs among patients with psoriasis in Japan: a retrospective database study.
    Wang C; Torisu-Itakura H; Hanada T; Matsuo T; Cai Z; Osaga S; Aranishi T
    J Dermatolog Treat; 2023 Dec; 34(1):2229465. PubMed ID: 37403477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease.
    Reich K; Warren RB; Coates LC; Di Comite G
    J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1161-1173. PubMed ID: 31785165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world biologic and apremilast treatment patterns in patients with psoriasis and psoriatic arthritis.
    Feldman SR; Zhang J; Martinez DJ; Lopez-Gonzalez L; Hoit Marchlewicz E; Shrady G; Zhao Y; Mendelsohn AM
    Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Behçet disease with psoriasis and psoriatic arthritis.
    Hahn HJ; Kwak SG; Kim DK; Kim JY
    Sci Rep; 2021 Jan; 11(1):2531. PubMed ID: 33510251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective.
    Aiello E; Bianculli PM; Bhattacharyya D; Gunda P; Citera G
    Value Health Reg Issues; 2019 Dec; 20():86-94. PubMed ID: 31103950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis receiving methotrexate: A population-based study.
    Gelfand JM; Wan J; Zhang H; Shin DB; Ogdie A; Syed MN; Egeberg A
    J Am Acad Dermatol; 2021 Jun; 84(6):1636-1643. PubMed ID: 33607181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany.
    Gandjour A; Ostwald DA
    Appl Health Econ Health Policy; 2020 Feb; 18(1):109-125. PubMed ID: 31701482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early diagnosis of psoriatic arthritis among psoriasis patients: clinical experience sharing.
    Su YJ
    Clin Rheumatol; 2020 Dec; 39(12):3677-3684. PubMed ID: 32468320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin 23 versus interleukin 12/23 inhibitors on preventing incidental psoriatic arthritis in patients with psoriasis? A real-world comparison from the TriNetX Global Collaborative Network.
    Tsai SHL; Yang CY; Huo AP; Wei JC
    J Am Acad Dermatol; 2024 Nov; 91(5):889-895. PubMed ID: 39079603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database.
    Pina Vegas L; Penso L; Claudepierre P; Sbidian E
    JAMA Dermatol; 2022 May; 158(5):513-522. PubMed ID: 35319735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of Musculoskeletal Symptoms in Patients with Psoriasis and Predictors Associated with the Development of Psoriatic Arthritis: Retrospective Analysis of a US Claims Database.
    Merola JF; Patil D; Egana A; Steffens A; Webb NS; Gottlieb AB
    Dermatol Ther (Heidelb); 2023 Nov; 13(11):2635-2648. PubMed ID: 37726542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.